PATENTED INGREDIENT
Brainberry®
Brainberry® is a patented ingredient in the ACC Biotech catalogue, developed by BioActor B.V., with Netherlands listed as its origin. This page brings together the ingredient information currently available from ACC Biotech and the enquiry route.
INGREDIENT PROFILE
What this ingredient is documented for
- Origin
- Netherlands
- Developer
- BioActor B.V.
- High Anthocyanin Content: Standardized to ≥15% cyanidin‑3‑O‑galactoside, supporting antioxidant protection and cognitive health.
- Clinically Proven Efficacy: Just 65 mg/day improves focus, hand–eye coordination, and cognitive speed, with BDNF levels increasing up to +43% over 12 weeks.
- Brain Bioavailability: Crosses the blood-brain barrier to enhance oxygenation and stimulate BDNF (brain-derived neurotrophic factor).
- Patent-Protected & Well Studied: Covered by US patent (on dose and effect); supported by placebo-controlled studies (7 days to 12 weeks).
- Clean Label & Versatile: 100% natural, stimulant-free, and highly water-soluble—ideal for use in sachets, tablets, gummies, and beverages.
QUICK REFERENCE
Key ingredient facts
- Origin
- Netherlands
- Developer
- BioActor B.V.
About Brainberry®
Brainberry® is a patented ingredient in the ACC Biotech catalogue, developed by BioActor B.V., with Netherlands listed as its origin. This page brings together the ingredient information currently available from ACC Biotech and the enquiry route.
Frequently asked questions
These answers summarize ACC Biotech's current catalogue information and enquiry process.
What information is available for Brainberry®?
This page summarizes the ingredient highlights, origin and developer information currently held in the ACC Biotech catalogue.
How can I request formulation, documentation or sourcing details?
Contact ACC Biotech with the intended dosage form, market and document requirements so the team can follow up with the relevant information.
FORMULATION
Discuss this ingredient with ACC
Bring this ingredient into a formula, documentation and sourcing conversation with the ACC team.